Loading...
XJSEAPN
Market cap4.22bUSD
Dec 20, Last price  
17,377.00ZAR
1D
5.00%
1Q
-8.45%
Jan 2017
-38.72%
Name

Aspen Pharmacare Holdings Ltd

Chart & Performance

D1W1MN
XJSE:APN chart
P/E
1,476.56
P/S
189.62
EPS
11.77
Div Yield, %
0.02%
Shrs. gr., 5y
-0.54%
Rev. gr., 5y
-0.90%
Revenues
44.71b
+9.82%
2,869,031,0003,449,340,0004,025,854,0004,881,273,0008,450,300,00010,146,600,00012,383,200,00015,255,800,00019,308,000,00029,515,100,00036,126,600,00035,600,000,00041,200,000,00042,596,000,00038,872,000,00038,647,000,00037,766,000,00038,606,000,00040,709,000,00044,706,000,000
Net income
4.40b
-15.76%
493,991,000638,093,000717,666,000864,476,0001,353,600,0001,978,500,0002,588,800,0002,817,800,0003,520,100,0005,007,600,0005,201,400,0004,300,000,0005,100,000,0006,010,000,0006,463,000,0004,664,000,0004,806,000,0006,488,000,0005,228,000,0004,404,000,000
CFO
6.23b
+12.77%
638,203,000402,213,000708,560,000652,384,0001,292,100,0002,033,000,0002,445,900,0002,908,400,0003,986,100,0003,836,300,0004,838,800,0003,200,000,0006,500,000,0007,017,000,0006,002,000,0008,260,000,0006,825,000,0005,374,000,0005,520,000,0006,225,000,000
Dividend
Sep 18, 2024359 ZAR/sh
Earnings
Mar 03, 2025

Profile

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
URL
http://www.aspenpharma.com/
IPO date
Dec 05, 1994
Employees
8,580
Domiciled in
ZA
Incorporated in
ZA

Valuation

Title
ZAR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
44,706,000
9.82%
40,709,000
5.45%
38,606,000
2.22%
Cost of revenue
35,552,000
27,114,000
25,129,000
Unusual Expense (Income)
NOPBT
9,154,000
13,595,000
13,477,000
NOPBT Margin
20.48%
33.40%
34.91%
Operating Taxes
1,310,000
1,327,000
1,646,000
Tax Rate
14.31%
9.76%
12.21%
NOPAT
7,844,000
12,268,000
11,831,000
Net income
4,404,000
-15.76%
5,228,000
-19.42%
6,488,000
35.00%
Dividends
(1,525,000)
(1,455,000)
(1,196,000)
Dividend yield
Proceeds from repurchase of equity
(56,000)
(136,000)
15,661,000
BB yield
Debt
Debt current
11,314,000
7,907,000
11,665,000
Long-term debt
25,737,000
21,647,000
10,927,000
Deferred revenue
1,177,000
10,000
Other long-term liabilities
3,191,000
353,000
4,480,000
Net debt
24,060,000
18,377,000
16,058,000
Cash flow
Cash from operating activities
6,225,000
5,520,000
5,374,000
CAPEX
(5,535,000)
(3,181,000)
(2,697,000)
Cash from investing activities
(9,468,000)
(3,421,000)
(2,161,000)
Cash from financing activities
3,623,000
(420,000)
(4,676,000)
FCF
4,780,000
7,896,000
16,638,000
Balance
Cash
12,337,000
10,912,000
6,183,000
Long term investments
654,000
265,000
351,000
Excess cash
10,755,700
9,141,550
4,603,700
Stockholders' equity
85,225,000
86,584,000
127,300,000
Invested Capital
113,751,300
106,496,450
91,015,300
ROIC
7.12%
12.42%
13.28%
ROCE
7.26%
11.56%
13.81%
EV
Common stock shares outstanding
444,200
444,200
453,000
Price
Market cap
EV
EBITDA
11,127,000
15,383,000
15,190,000
EV/EBITDA
Interest
2,227,000
1,324,000
765,000
Interest/NOPBT
24.33%
9.74%
5.68%